SI1459765T1 - Derivati 6-florobiciklo 3.1.0 heksana - Google Patents
Derivati 6-florobiciklo 3.1.0 heksanaInfo
- Publication number
- SI1459765T1 SI1459765T1 SI200230736T SI200230736T SI1459765T1 SI 1459765 T1 SI1459765 T1 SI 1459765T1 SI 200230736 T SI200230736 T SI 200230736T SI 200230736 T SI200230736 T SI 200230736T SI 1459765 T1 SI1459765 T1 SI 1459765T1
- Authority
- SI
- Slovenia
- Prior art keywords
- group
- alkoxy
- represent
- fluorobicyclo
- different
- Prior art date
Links
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical class CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 title 1
- 125000002252 acyl group Chemical group 0.000 abstract 2
- 125000000027 (C1-C10) alkoxy group Chemical group 0.000 abstract 1
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 abstract 1
- 102000016193 Metabotropic glutamate receptors Human genes 0.000 abstract 1
- 108010010914 Metabotropic glutamate receptors Proteins 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 230000003042 antagnostic effect Effects 0.000 abstract 1
- 230000001430 anti-depressive effect Effects 0.000 abstract 1
- 239000000935 antidepressant agent Substances 0.000 abstract 1
- 229940005513 antidepressants Drugs 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/46—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino or carboxyl groups bound to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
- C07C229/50—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino or carboxyl groups bound to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups and carboxyl groups bound to carbon atoms being part of the same condensed ring system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
- C07C237/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/24—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring of the carbon skeleton
- C07C237/26—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring of the carbon skeleton of a ring being part of a condensed ring system formed by at least four rings, e.g. tetracycline
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C255/00—Carboxylic acid nitriles
- C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C255/54—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and etherified hydroxy groups bound to the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
- C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
- C07D333/16—Radicals substituted by singly bound hetero atoms other than halogen by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
- C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
- C07C2602/14—All rings being cycloaliphatic
- C07C2602/18—All rings being cycloaliphatic the ring system containing six carbon atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Addiction (AREA)
- Hospice & Palliative Care (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Heterocyclic Compounds Containing Sulfur Atoms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Heat Sensitive Colour Forming Recording (AREA)
- Glass Compositions (AREA)
- Lubricants (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2001395797 | 2001-12-27 | ||
| EP02793421A EP1459765B1 (en) | 2001-12-27 | 2002-12-26 | 6-fluorobicyclo 3.1.0 hexane derivatives |
| PCT/JP2002/013693 WO2003061698A1 (en) | 2001-12-27 | 2002-12-26 | 6-fluorobicyclo[3.1.0]hexane derivatives |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SI1459765T1 true SI1459765T1 (sl) | 2009-02-28 |
Family
ID=27602080
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SI200230736T SI1459765T1 (sl) | 2001-12-27 | 2002-12-26 | Derivati 6-florobiciklo 3.1.0 heksana |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US7157594B2 (sl) |
| EP (1) | EP1459765B1 (sl) |
| JP (1) | JP4230919B2 (sl) |
| KR (2) | KR20090031962A (sl) |
| CN (1) | CN1281274C (sl) |
| AT (1) | ATE405289T1 (sl) |
| AU (1) | AU2002359923B2 (sl) |
| BR (1) | BR0215462A (sl) |
| CA (1) | CA2471642C (sl) |
| CY (1) | CY1108380T1 (sl) |
| DE (1) | DE60228491D1 (sl) |
| DK (1) | DK1459765T3 (sl) |
| ES (1) | ES2311642T3 (sl) |
| HU (1) | HU228436B1 (sl) |
| MX (1) | MXPA04006322A (sl) |
| NO (1) | NO328844B1 (sl) |
| NZ (1) | NZ533699A (sl) |
| PL (1) | PL208123B1 (sl) |
| PT (1) | PT1459765E (sl) |
| RU (1) | RU2315622C2 (sl) |
| SI (1) | SI1459765T1 (sl) |
| WO (1) | WO2003061698A1 (sl) |
| ZA (2) | ZA200404795B (sl) |
Families Citing this family (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU1412702A (en) * | 2000-10-27 | 2002-05-06 | Chiron Spa | Nucleic acids and proteins from streptococcus groups a and b |
| DE60325968D1 (de) * | 2002-06-11 | 2009-03-12 | Lilly Co Eli | Prodrugs von exzitatorischen aminosäuren |
| US7109383B2 (en) * | 2002-09-27 | 2006-09-19 | Central Glass Company, Limited | Fluorine-containing allyl ether compounds, their copolymers, and resist compositions and anti-reflection film materials using such copolymers |
| US7960579B2 (en) | 2003-06-26 | 2011-06-14 | Taisho Pharmaceutical Co., Ltd. | 2-amino-bicyclo [3.1.0] hexane-2,6-dicarboxylic ester derivative |
| JP5485492B2 (ja) * | 2004-12-15 | 2014-05-07 | 大正製薬株式会社 | うつ病の予防・治療薬 |
| AU2006282896A1 (en) | 2005-08-26 | 2007-03-01 | Braincells, Inc. | Neurogenesis by muscarinic receptor modulation |
| EP2258357A3 (en) | 2005-08-26 | 2011-04-06 | Braincells, Inc. | Neurogenesis with acetylcholinesterase inhibitor |
| WO2007047978A2 (en) | 2005-10-21 | 2007-04-26 | Braincells, Inc. | Modulation of neurogenesis by pde inhibition |
| JP2009513672A (ja) | 2005-10-31 | 2009-04-02 | ブレインセルス,インコーポレイティド | 神経発生のgaba受容体媒介調節 |
| US20100216734A1 (en) | 2006-03-08 | 2010-08-26 | Braincells, Inc. | Modulation of neurogenesis by nootropic agents |
| AR059898A1 (es) | 2006-03-15 | 2008-05-07 | Janssen Pharmaceutica Nv | Derivados de 3-ciano-piridona 1,4-disustituida y su uso como moduladores alostericos de los receptores mglur2 |
| MX2008014320A (es) | 2006-05-09 | 2009-03-25 | Braincells Inc | Neurogenesis mediada por el receptor de 5-hidroxitriptamina. |
| EP2377531A2 (en) | 2006-05-09 | 2011-10-19 | Braincells, Inc. | Neurogenesis by modulating angiotensin |
| US7998971B2 (en) | 2006-09-08 | 2011-08-16 | Braincells Inc. | Combinations containing a 4-acylaminopyridine derivative |
| US20100184806A1 (en) | 2006-09-19 | 2010-07-22 | Braincells, Inc. | Modulation of neurogenesis by ppar agents |
| TW200845978A (en) | 2007-03-07 | 2008-12-01 | Janssen Pharmaceutica Nv | 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives |
| TW200900065A (en) | 2007-03-07 | 2009-01-01 | Janssen Pharmaceutica Nv | 3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives |
| US8722894B2 (en) | 2007-09-14 | 2014-05-13 | Janssen Pharmaceuticals, Inc. | 1,3-disubstituted-4-phenyl-1H-pyridin-2-ones |
| NZ584152A (en) | 2007-09-14 | 2011-11-25 | Ortho Mcneil Janssen Pharm | 1,3-disubstituted 4-(aryl-x-phenyl)-1h-pyridin-2-ones |
| SI2203439T1 (sl) | 2007-09-14 | 2011-05-31 | Ortho Mcneil Janssen Pharm | 1',3'-disubstituirani 4-fenil-3,4,5,6-tetrahidro-2H-1'H-(1,4')bipiridinil-2'-oni |
| RU2492170C9 (ru) | 2007-11-14 | 2013-12-27 | Орто-Макнейл-Янссен Фармасьютикалз, Инк. | Имидазо[1,2-а]пиридиновые производные и их применение в качестве положительных аллостерических модуляторов рецепторов mglur2 |
| AU2009289784B2 (en) | 2008-09-02 | 2012-03-22 | Addex Pharma S.A. | 3-azabicyclo[3.1.0]hexyl derivatives as modulators of metabotropic glutamate receptors |
| US8697689B2 (en) | 2008-10-16 | 2014-04-15 | Janssen Pharmaceuticals, Inc. | Indole and benzomorpholine derivatives as modulators of metabotropic glutamate receptors |
| WO2010060589A1 (en) | 2008-11-28 | 2010-06-03 | Ortho-Mcneil-Janssen Pharmaceuticals, Inc. | Indole and benzoxazine derivatives as modulators of metabotropic glutamate receptors |
| WO2010099217A1 (en) | 2009-02-25 | 2010-09-02 | Braincells, Inc. | Modulation of neurogenesis using d-cycloserine combinations |
| BRPI1010831A2 (pt) | 2009-05-12 | 2016-04-05 | Addex Pharmaceuticals Sa | derivados de 1,2,4-triazolo[4,3-a]piridina e seu como moduladores alostéricos positivos de receptores de mglur2 |
| CN102439008B (zh) | 2009-05-12 | 2015-04-29 | 杨森制药有限公司 | 1,2,4-三唑并[4,3-a]吡啶衍生物及其用于治疗或预防神经和精神病症的用途 |
| MY153913A (en) | 2009-05-12 | 2015-04-15 | Janssen Pharmaceuticals Inc | 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors |
| US8742161B2 (en) | 2009-11-18 | 2014-06-03 | Taisho Pharmaceutical Co., Ltd | Process for producing optically active bicyclo [3.1.0] hexane derivative using enzyme |
| TW201124372A (en) | 2009-11-19 | 2011-07-16 | Taisho Pharmaceutical Co Ltd | Process for producing 3-alkoxy-2-amino-6-fluorobicyclo[310]hexane-2,6-dicarboxylic acid derivative and intermediate thereof |
| PT2649069E (pt) | 2010-11-08 | 2015-11-20 | Janssen Pharmaceuticals Inc | Derivados de 1,2,4-triazolo[4,3-a]piridina e sua utilização como moduladores alostéricos positivos de recetores mglur2 |
| JP5852665B2 (ja) | 2010-11-08 | 2016-02-03 | ジヤンセン・フアーマシユーチカルズ・インコーポレーテツド | 1,2,4−トリアゾロ[4,3−a]ピリジン誘導体およびmGluR2受容体のポジティブアロステリックモジュレーターとしてのそれらの使用 |
| WO2012062759A1 (en) | 2010-11-08 | 2012-05-18 | Janssen Pharmaceuticals, Inc. | 1,2,4-TRIAZOLO[4,3-a]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS |
| KR101554793B1 (ko) | 2010-11-18 | 2015-09-21 | 일라이 릴리 앤드 캄파니 | mGluR 2/3 길항제로서의 4-치환된-3-벤질옥시-비시클로[3.1.0]헥산 화합물 |
| AR083845A1 (es) | 2010-11-18 | 2013-03-27 | Lilly Co Eli | COMPUESTOS 3-FENILSULFANILMETIL-BICICLO[3.1.0]HEXANO 4-SUSTITUIDOS COMO ANTAGONISTAS DE mGluR2/3 |
| US9296710B2 (en) | 2011-06-17 | 2016-03-29 | Eli Lilly And Company | Bicyclo (3.1.0) hexane-2, 6-dicarboxylic acid derivatives as mGlu2 receptor agonist |
| WO2013062680A1 (en) * | 2011-10-25 | 2013-05-02 | Braincells, Inc. | Novel compounds and compositions thereof for treating nervous system disorders |
| RU2496495C2 (ru) * | 2011-12-05 | 2013-10-27 | Учреждение Российской академии медицинских наук Научно-исследовательский институт нормальной физиологии имени П.К. Анохина РАМН | ПРИМЕНЕНИЕ СЕЛЕКТИВНОГО АНТАГОНИСТА ГЛУТАМАТНЫХ РЕЦЕПТОРОВ Ro-256981 ДЛЯ НАПРАВЛЕННОГО ВЛИЯНИЯ НА КОГНИТИВНЫЕ ФУНКЦИИ |
| BR112014029478B1 (pt) * | 2012-06-01 | 2023-01-17 | Taisho Pharmaceutical Co., Ltd | Compostos, fármacos de aminoácido contendo flúor e uso destes |
| JO3368B1 (ar) | 2013-06-04 | 2019-03-13 | Janssen Pharmaceutica Nv | مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2 |
| JO3367B1 (ar) | 2013-09-06 | 2019-03-13 | Janssen Pharmaceutica Nv | مركبات 2،1، 4- ثلاثي زولو [3،4-a] بيريدين واستخدامها بصفة منظمات تفارغية موجبة لمستقبلات ميجلور 2 |
| ES2860298T3 (es) | 2014-01-21 | 2021-10-04 | Janssen Pharmaceutica Nv | Combinaciones que comprenden moduladores alostéricos positivos del receptor glutamatérgico metabotrópico de subtipo 2 y su uso |
| AU2015208233B2 (en) | 2014-01-21 | 2019-08-29 | Janssen Pharmaceutica Nv | Combinations comprising positive allosteric modulators or orthosteric agonists of metabotropic glutamatergic receptor subtype 2 and their use |
| RU2739318C2 (ru) | 2016-04-18 | 2020-12-22 | Тайсо Фармасьютикал Ко., Лтд. | Пролекарство производного аминокислоты |
| JP7314494B2 (ja) * | 2017-10-17 | 2023-07-26 | 大正製薬株式会社 | アミノ酸誘導体のプロドラッグを含有する医薬 |
| JP2024004505A (ja) * | 2020-11-26 | 2024-01-17 | 大正製薬株式会社 | アミノ酸誘導体の製造方法 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2000500752A (ja) | 1995-11-16 | 2000-01-25 | イーライ・リリー・アンド・カンパニー | 興奮性アミノ酸受容体アンタゴニスト |
| ZA969485B (en) | 1995-11-16 | 1998-05-12 | Lilly Co Eli | Excitatory amino acid receptor antagonists. |
| ZA983930B (en) * | 1997-05-14 | 1999-11-08 | Lilly Co Eli | Excitatory amino acid receptor modulators. |
| JP4194715B2 (ja) | 1998-08-31 | 2008-12-10 | 大正製薬株式会社 | 6−フルオロビシクロ[3.1.0]ヘキサン誘導体 |
| CN1247527C (zh) | 1998-08-31 | 2006-03-29 | 大正制药株式会社 | 6-氟双环[3.1.0]己烷衍生物 |
| CH694053A5 (de) | 1998-09-03 | 2004-06-30 | Hoffmann La Roche | Verfahren zur Herstellung von 2-Amino-bicyclo[3.1.0]hexan-2,6-dicarbonsäure-Derivaten. |
| AU5667900A (en) * | 1999-06-30 | 2001-01-22 | Prescient Neuropharma Inc. | 2-aminoindane analogs |
| MXPA02011053A (es) * | 2000-05-11 | 2004-08-19 | Kenneth Curry | Compuestos novedosos de carboxi amino espiro (2,4)heptano y derivados de los mismos. |
| EP1295865A4 (en) * | 2000-06-28 | 2005-06-01 | Taisho Pharmaceutical Co Ltd | NEW DICARBOXYLENE DERIVATIVES |
| JP4071115B2 (ja) * | 2001-04-12 | 2008-04-02 | エフ.ホフマン−ラ ロシュ アーゲー | mGluR2アンタゴニストIIとしてのジヒドロ−ベンゾ〔b〕〔1,4〕ジアゼピン−2−オン誘導体 |
-
2002
- 2002-12-26 KR KR1020097005135A patent/KR20090031962A/ko not_active Withdrawn
- 2002-12-26 KR KR1020047010069A patent/KR100897970B1/ko not_active Expired - Fee Related
- 2002-12-26 AU AU2002359923A patent/AU2002359923B2/en not_active Ceased
- 2002-12-26 EP EP02793421A patent/EP1459765B1/en not_active Expired - Lifetime
- 2002-12-26 DK DK02793421T patent/DK1459765T3/da active
- 2002-12-26 CA CA2471642A patent/CA2471642C/en not_active Expired - Fee Related
- 2002-12-26 ES ES02793421T patent/ES2311642T3/es not_active Expired - Lifetime
- 2002-12-26 PL PL371014A patent/PL208123B1/pl unknown
- 2002-12-26 MX MXPA04006322A patent/MXPA04006322A/es active IP Right Grant
- 2002-12-26 WO PCT/JP2002/013693 patent/WO2003061698A1/ja not_active Ceased
- 2002-12-26 SI SI200230736T patent/SI1459765T1/sl unknown
- 2002-12-26 BR BR0215462-5A patent/BR0215462A/pt not_active IP Right Cessation
- 2002-12-26 CN CNB02826388XA patent/CN1281274C/zh not_active Expired - Fee Related
- 2002-12-26 JP JP2003561641A patent/JP4230919B2/ja not_active Expired - Fee Related
- 2002-12-26 US US10/500,101 patent/US7157594B2/en not_active Expired - Fee Related
- 2002-12-26 AT AT02793421T patent/ATE405289T1/de active
- 2002-12-26 RU RU2004122916/15A patent/RU2315622C2/ru not_active IP Right Cessation
- 2002-12-26 NZ NZ533699A patent/NZ533699A/en not_active IP Right Cessation
- 2002-12-26 HU HU0402649A patent/HU228436B1/hu not_active IP Right Cessation
- 2002-12-26 DE DE60228491T patent/DE60228491D1/de not_active Expired - Lifetime
- 2002-12-26 PT PT02793421T patent/PT1459765E/pt unknown
-
2004
- 2004-06-16 NO NO20042530A patent/NO328844B1/no not_active IP Right Cessation
- 2004-06-17 ZA ZA2004/04795A patent/ZA200404795B/en unknown
-
2005
- 2005-03-11 ZA ZA2005/02085A patent/ZA200502085B/en unknown
-
2008
- 2008-09-29 CY CY20081101068T patent/CY1108380T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60228491D1 (en) | 6-fluorobicyclo 3.1.0 hexan-derivate | |
| ATE193828T1 (de) | Hypoglykämische dihydrochalconderivate | |
| WO2002010154A3 (en) | Substituted heterocyclic amides | |
| DE69528005D1 (de) | Prolineamid-Derivate | |
| ATE268751T1 (de) | Biphenylamidin-derivate | |
| DE60104697D1 (de) | Sulfonamid-derivate | |
| WO2003035610A1 (en) | Sulfonamide derivative having mmp inhibitory activity | |
| AU2001269540A1 (en) | Serotonin reuptake inhibitors | |
| AU2318600A (en) | Chondrongenesis promotors and indolin-2-one derivatives | |
| AU6518798A (en) | 2-phenoxyaniline derivatives | |
| EP1034783A4 (en) | AMIDE DERIVATIVES | |
| AU2001228862A1 (en) | Remedies or preventives for liver diseases containing diaminotrifluoromethylpyridine derivatives | |
| EP1734046A4 (en) | radiosensitizer | |
| EP1306368A3 (en) | 3,4-dihydro-1H-naphtalene derivatives as a highly selective cyclooxygenase-2 inhibitor | |
| EP1650210A4 (en) | THERAPEUTIC AGENT AGAINST HYPERKALEMIA AND BONE DISEASE | |
| AU7962000A (en) | Us0027324for eating disorders | |
| IL166313A0 (en) | Indoline derivatives and pharmaceutical compositions containing the same | |
| DE60001205D1 (de) | Azolderivative oder deren Salze | |
| DE60203029D1 (de) | Benzopyran Derivate und diese enthaltende Antiallergisches Mittel |